BACKGROUND CD30 ligand (CD30L), a member of the TNF family, is a type II membrane protein with a C-terminal extracellular domain that is homologous with the extracellular domains of other TNF family members. Also, like most TNF family members, the N-terminal cytoplasmic domain of CD30L is conserved across species, but not between family members, suggesting a possible biological function.1 CD30L mediates its signalling through CD30, a transmembrane receptor typically expressed on Hodgkin-Reed-Sternberg (H-RS) cells of Hodgkin's disease (HD) and on malignant cells of anaplastic large-cell lymphoma (ALCL).2 CD30L has been previously shown to be expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. Recombinant CD30L stimulates the proliferation of cultured H-RS cells, either directly or indirectly by enhancing the release of a number of cytokines such as interleukin-6 (IL-6), TNF, and LT- . Similarly, CD30L induces the expression of surface accessory molecules (CD54, CD80, and CD86) on activated T cells, along with the secretion of both Th1- and Th2-type cytokines, including TNF, IL-2, interferon- , IL-4, and IL-5. Moreover, CD30/CD30L interactions can have a direct positive or negative effect on mouse and human B-cell proliferation and/or differentiation.3 Both CD30L and CD30 display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. Upregulation of CD30 and CD30L is linked to leukocytes in patients with various diseases. Preclinical studies conducted with transgenic mice or biologic compounds suggested important regulatory functions of the CD30-CD30L system in various aspects of the immune system. Such key regulatory roles and their low expression in normal conditions combined with increased expression in malignant tissues provided a strong rationale to investigate CD30 and CD30L as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases.4
1. Kennedy, M.K. et al: Immunol. 118:143-52, 2006
2. Gruss, H-J. & Herrmann, F.: Leuk Lymphoma. 20:397-409, 1996
3. Shanebeck, K.D. Et al: Eur. J. Immunol. 25: 2147-53, 1995
4. Oflazoglu, E. et al: Adv Exp Med Biol. 647:174-85, 2009
Products are for research use only. They are not intended for human, animal, or diagnostic applications.
Target Protein Species:
15.6 pg/ml – 1000pg/ml
No detectable cross-reactivity
with other cytokines
Store at 4°C. Use within 6 months.
ELISA Kits are based on standard sandwich enzyme-linked immunosorbent assay technology. Freshly prepared standards, samples, and solutions are recommended for best results.